TD Cowen maintains Buy rating on Incyte, $140 price target
TD Cowen reaffirmed a Buy rating on Incyte with a $140 price target, suggesting a 20.1% upside from the Oct 20 close. Jakafi sales grew 8% YoY to $2.59B in 2023, with peak U.S. sales projected to exceed $3B. Incyte's pipeline, including Opzelura, is expected to drive future revenue growth.
How this was made
The 30-second read
Why it matters
The upgrade and target could trigger buying pressure and raise the stock's valuation.
Market read
Analyst rating change is a primary catalyst for short-term price movement.
What to watch
Potential regulatory or reimbursement challenges for new pipeline products.
Background
TD Cowen issued an analyst note maintaining a Buy rating on Incyte (INCY) with a $140 price target.
Ticker impact
TD Cowen upgraded its rating to Buy and set a $140 price target, implying 20% upside.
likely upward pressure as investors price in the new target
Buy rating and a sizable upside target are fresh analyst actions that can move the stock.
Market effects
May boost sentiment in the biotech sector as analysts raise expectations.
Limited to US biotech investors.
Low global impact.
Counterpoint
The target may be overly optimistic given competitive pressures on Jakafi.
Key entities
- companyIncyte
Biotech firm developing oncology and dermatology drugs.
- analyst_firmTD Cowen
Equity research firm providing the rating.
